These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17322487)

  • 21. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis.
    Härle P; Sarzi-Puttini P; Cutolo M; Straub RH
    Ann Rheum Dis; 2006 Jul; 65(7):970-1. PubMed ID: 16769786
    [No Abstract]   [Full Text] [Related]  

  • 22. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

  • 23. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
    Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
    Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
    Egnatios G; Warthan MM; Pariser R; Hood AF
    J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
    [No Abstract]   [Full Text] [Related]  

  • 26. [Adalimumab in the treatment of rheumatoid arthritis].
    Bendtzen K
    Ugeskr Laeger; 2004 Jun; 166(26-31):2552-4. PubMed ID: 15285162
    [No Abstract]   [Full Text] [Related]  

  • 27. Skin reaction to adalimumab.
    Beuthien W; Mellinghoff HU; von Kempis J
    Arthritis Rheum; 2004 May; 50(5):1690-2. PubMed ID: 15146441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): p38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis.
    Aerts NE; Ebo DG; Bridts CH; Stevens WJ; De Clerck LS
    Cytokine; 2009 Sep; 47(3):178-84. PubMed ID: 19616965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study.
    Raterman HG; Jamnitski A; Lems WF; Voskuyl AE; Dijkmans BA; Bos WH; Simsek S; Lips P; van de Stadt RJ; de Koning MH; Nurmohamed MT
    J Rheumatol; 2011 Feb; 38(2):247-51. PubMed ID: 21078720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [What is special about adalimumab?].
    Rodríguez-Blanco I; Toribio J
    Actas Dermosifiliogr; 2008 Feb; 99 Suppl 3():28-32. PubMed ID: 18680688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 35. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab in the therapy of uveitis in childhood.
    Biester S; Deuter C; Michels H; Haefner R; Kuemmerle-Deschner J; Doycheva D; Zierhut M
    Br J Ophthalmol; 2007 Mar; 91(3):319-24. PubMed ID: 17035274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.
    Schiff MH; Burmester GR; Kent JD; Pangan AL; Kupper H; Fitzpatrick SB; Donovan C
    Ann Rheum Dis; 2006 Jul; 65(7):889-94. PubMed ID: 16439435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.